datma Enhances Real-World Data Network with Genomic Insights
datma's Revolutionary Expansion in Data Network
datma, a notable leader in federated real-world data access, has achieved a significant milestone, announcing that its federated data marketplace now encompasses over one million records available for in-depth research. This expansion highlights the immense value of datma.FED, a platform designed for secure and federated access to high-quality data sets that include demographic, electronic health records (EHR), genomic, and pathology data. This capability is crucial for pharmaceutical companies and research organizations that require insights typically absent in traditional real-world data environments.
Power of Federated Access
The growth of datma.FED equips pharmaceutical and research entities with scalable access to crucial contextual and longitudinal insights derived from genomic and pathology data. In contrast to earlier data models that often necessitated cumbersome data transfers or centralized databases, datma.FED facilitates secure federated queries. This ensures that data custodians retain complete control over their datasets, while enabling researchers access to vital real-world oncology information.
Feedback from Leadership
CEO Noah Nasser expressed enthusiasm regarding this milestone, stating, "This achievement markedly enhances the richness and quality of real-world genomic data provided through datma.FED." With more than one million patient records now accessible, researchers and pharmaceutical teams can delve into real-world data, allowing for an exploration of genomic testing utilization patterns while maintaining stringent privacy and data stewardship standards. By aligning the right data with the right researchers, datma accelerates the pace of discovery without the traditional challenges associated with data sharing.
Bridging Gaps in Molecular Data
The integration of advanced molecular profiling and comprehensive genomic datasets is a game-changer for the pharmaceutical industry as it addresses existing gaps in real-world datasets. Although claims and EHR data can shed light on diagnoses and treatments, they often lack essential details regarding molecular testing. By incorporating genomic and pathology data into the landscape, pharma can evaluate the prevalence of biomarkers, assess trends in molecular testing, and pinpoint gaps in testing uptake. These valuable insights enable pharma teams to refine their market access strategies and enhance commercialization efforts.
Compliance and Efficiency
datma.FED’s federated model is designed with compliance in mind, strictly adhering to HIPAA regulations and other necessary standards, while removing the burdens associated with manual data preparation and integration. The platform takes care of ingesting, standardizing, and harmonizing healthcare data, making it readily usable for pharmaceutical and research teams. As datma continues to expand its network offerings, it remains committed to narrowing the chasm between real-world data and its application in innovative research and precision medicine developments.
About datma
datma stands as a distinguished provider of federated real-world data platforms, along with tools designed for comprehensive analysis and visualization. The organization’s mission focuses on empowering healthcare entities to maximize their data assets, drive innovations, and enhance patient outcomes through sophisticated data storage, AI-driven data harmonization, and federated queries. With headquarters in Oregon, datma is spearheading the transformation of healthcare data sharing, monetization, and application, fostering secure collaborations between data custodians and consumers. This initiative facilitates the analysis of extensive decentralized datasets, safeguarding privacy while paving the way for innovative advancements.
Media Contact
For further inquiries, please reach out to Vikki Herrera from Oak Street Communications.
Frequently Asked Questions
What is the main focus of datma's recent announcement?
datma has announced the expansion of its real-world data marketplace, surpassing one million records available for research.
How does datma.FED ensure data security?
datma.FED allows secure federated queries, enabling data custodians to maintain control over their datasets while researchers access essential information.
What kinds of insights can researchers gain from datma's platform?
Researchers can explore genomic testing patterns, biomarker prevalence, and trends in molecular testing utilization through the genomic and pathology data provided.
How does datma support compliance in data handling?
datma.FED adheres to HIPAA and other regulatory standards, streamlining data management while ensuring privacy and security.
What is datma's mission in healthcare?
datma aims to empower healthcare organizations to optimize data usage, foster innovation, and improve patient outcomes through advanced data technologies.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
